Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise
Purchase & earn 25 points
FDA concluded that based on the available evidence, that the supply of semaglutide meets or exceeds current demand, and that, based on our best judgment looking at the available information with its limitations, supply will meet or exceed projected demand. FDA acknowledges in the Declaratory Order that: [E]ven when a shortage is considered resolved, patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain from the manufacturer and distributors to local pharmacies
However, the rising demand for Ozempic, coupled with manufacturer shortages, has made harder to access the medication
